LitCovid-sentences  

PMC:7600245 / 56516-57958 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T425 0-86 Sentence denotes Sirolimus is a natural macrolide (Figure S5) obtained from Streptomyces hygroscopicus.
T426 87-120 Sentence denotes It was first approved by the U.S.
T427 121-207 Sentence denotes FDA in 1999 and is orally used for lymphangioleiomyomatosis and renal transplantation.
T428 208-325 Sentence denotes Mechanistically, the drug is an immunosuppressive agent and an inhibitor of the mammalian target of rapamycin (mTOR).
T429 326-466 Sentence denotes Sirolimus forms an immunosuppressive complex with FK-binding protein-12, and subsequently, the complex inhibits the regulatory kinase, mTOR.
T430 467-588 Sentence denotes This inhibition suppresses cytokine mediated proliferation of T and B cells as well as the antibody production [180,181].
T431 589-745 Sentence denotes Furthermore, the drug may influence the virus because mTOR complex 1 is involved in the replication of various viruses, including coronavirus [182,183,184].
T432 746-866 Sentence denotes Furthermore, in vitro studies demonstrated a specific inhibitory activity against MERS-CoV infection by sirolimus [184].
T433 867-1120 Sentence denotes In an open-label, prospective randomized study in H1N1 pneumonia patients, treatment with sirolimus and corticosteroids combination for two weeks alleviated hypoxia, shortened the mechanical ventilation duration, and improved multi-organ function [185].
T434 1121-1281 Sentence denotes Accordingly, sirolimus is being tested for the treatment of COVID-19 patients either alone or in combination with hydroxychloroquine in several clinical trials.
T435 1282-1442 Sentence denotes Likewise, RTB101 (dactolisib), another mTOR inhibitor and phosphoinositide 3-kinase inhibitor, is also being tested in COVID-19 patients (NCT04409327; n = 550).